Nanogen, of San Diego, has appointed Ira Marks as its new vice president of business development. (See story p. 3) Marks comes to Nanogen from the San Diego-based Raichem division of Hemagen Diagnostics, which develops immunoassays for hospitals, laboratories, and doctors’ offices. Previously, Marks worked for 14 years at Bio-Rad Laboratories.
The company separately announced the resignation of Vera Pardee, vice president, general counsel, and secretary. Randy Bertholtz, who has been working with Nanogen since February 2000, will assume the role of acting general counsel and secretary.
Small molecule microarray maker Graffinity Pharmaceuticals, of Heidelberg, Germany, has appointed Victor Matassa as vice president of R&D. Matassa will develop Graffinity’s medicinal chemistry development, as part of its drug discovery and development efforts. Prior to joining Graffinity, Matassa was senior director of medicinal chemistry at Eli Lilly Europe. Matassa has also worked as a director of medicinal chemistry at Merck and AstraZeneca.
Microfluidics LabChip maker Caliper Technologies has appointed Susan Evans as vice president of product development. Evans will oversee all Caliper’s product development efforts, including new products and line extensions.
Evans, a biochemist, is president-elect of the American Association for Clinical Chemistry. Before joining Caliper, Evans held the position of vice president of research & development at Life Scan, a subsidiary of Johnson & Johnson. Evans also worked as senior vice president of R&D at clinical diagnostics company Dade Behring, and at Baxter Diagnostics.
Rockefeller University President Arnold Levine, a renowned cancer biologist who co-discovered the p53 tumor suppressor gene, resigned Sunday, amid swirling controversy over an alleged on-premises sexual encounter with a female adult student while both had been drinking. Rockefeller officially said Levine was resigning for health reasons.
Levine, who will remain a professor and researcher at Rockefeller, most recently co-authored a chapter on microarray analysis of colorectal tumors in a book Microarrays and Cancer Research, published this month by BioTechniques Press.